Show simple item record

dc.contributor.authorOzdemir, FA
dc.contributor.authorAnilanmert, B
dc.contributor.authorPekin, M
dc.date.accessioned2021-03-05T14:50:48Z
dc.date.available2021-03-05T14:50:48Z
dc.date.issued2005
dc.identifier.citationOzdemir F., Anilanmert B., Pekin M., "Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCI and epirubicin-HCI in the same infusion solution", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.56, ss.529-534, 2005
dc.identifier.issn0344-5704
dc.identifier.otherav_b91b86ce-6f75-4e5d-92da-8d18dc4e5b28
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/123164
dc.identifier.urihttps://doi.org/10.1007/s00280-004-0990-z
dc.description.abstractThe use of infusional chemotherapy, especially in an ambulatory setting, absolutely requires that the individual agents remain stable in solution at room temperature and that the drugs be compatible. Because of this, investigation of the chemical compatibilities of chemotherapeutic drug combinations given in the same infusion solution is quite important especially if the drugs are to remain in solution for long periods. Thus, the visual and chemical compatibility of irinotecan and epirubicin in the same infusion solution were investigated using both reference standards and pharmaceutical dosage forms. No sign of incompatibility was observed upon visual examination by means of effervescence, pH change, precipitation and colour change. But a chemical incompatibility was observed using a spectrophotometric method in the spectra of irinotecan-HCl and epirubicin-HCl. The molar ratio of epirubicin-HCl/irinotecan-HCl at which the interaction reached a maximum was found to be 2:1. The chemical interaction occurred immediately after admixing and no visual or spectral change was noticed for 24 h after the interaction had occurred. It is concluded that these drugs are chemically incompatible. While the applicability of these two drugs in combination is investigated in further pharmacological studies, their chemical interaction should also be a consideration. The positive or negative contribution of this interaction to the pharmacological effect of the combination might be of importance, and therefore should be investigated in further clinical trials.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleSpectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCI and epirubicin-HCI in the same infusion solution
dc.typeMakale
dc.relation.journalCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.contributor.department, ,
dc.identifier.volume56
dc.identifier.issue5
dc.identifier.startpage529
dc.identifier.endpage534
dc.contributor.firstauthorID100233


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record